Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Originally developed for multiple myeloma, felzartamab is a fully human IgG1 monoclonal CD38 antibody that depletes ... to diagnose graft injury. Median CD16 bright natural killer cell count ...

Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is ... rather than the CD16 and NKG2D receptors targeted by other bispecifics.